Announcements

Bristol-Myers Squibb, Medicines Patent Pool Extend Licence for Atazanavir to 122 Developing Countries

Extension of 2013 agreement allows an additional 1.4 million people living with HIV to benefit from sublicensed generics of World Health Organization-recommended antiretroviral Paris, 25 July 2017 — The Medicines Patent Pool (MPP) has signed an extension of its licensing agreement with biopharmaceutical company Bristol-Myers Squibb (BMS) to further increase access … Read more

The Medicines Patent Pool Governance Board Appoints Marie-Paule Kieny as new Chair

Former World Health Organization Assistant Director-General brings more than four decades of experience in public health systems and innovation to the MPP. Geneva, 3 July 2017 — The Medicines Patent Pool (MPP) Governance Board today announced the appointment of Dr. Marie-Paule Kieny as its new chair, effective 1 September 2017. … Read more

(Statement) The Medicines Patent Pool on the Inclusion of its Licensed Antiretrovirals on the World Health Organization’s New Essential Medicines List

  Geneva, 7 June 2017 — The Medicines Patent Pool welcomes yesterday’s publication of the World Health Organization (WHO)’s Model list of essential medicines (EML) for 2017, and particularly the inclusion of MPP-licensed dolutegravir, WHO-recommended as an alternative HIV first-line treatment. Updated every two years, the WHO’s list is an … Read more

The Medicines Patent Pool Publishes Analysis of Projected Savings of its Licensing Agreements in Peer-Reviewed Journal

Direct Savings to the Global Health Community Estimated to Reach $2.3 billion by 2028 Geneva, 1 June 2017 — The Medicines Patent Pool (MPP) published a study in peer-reviewed journal PLOS ONE estimating that savings of its licensing agreements for antiretrovirals (ARVs) to treat HIV in low- and middle-income countries could … Read more

The Medicines Patent Pool and Pharco Pharmaceuticals Sign Licence for Promising Hepatitis C Drug Candidate Ravidasvir

Agreement seeks to improve health options for hepatitis C patients in low- and middle-income countries   Amsterdam, Netherlands, 21 April 2017 —The Medicines Patent Pool (MPP) announced a new licence and technology transfer agreement with Egyptian company Pharco Pharmaceuticals for ravidasvir, an investigational direct-acting antiviral (DAA) with the potential of … Read more

TB Alliance Sublicenses Promising Anti-Tuberculosis Drug from the Medicines Patent Pool

Agreement announced on World Tuberculosis Day revitalizes efforts to develop sutezolid as effective response to infectious disease killer NEW YORK and GENEVA, 24 March 2017 — On World Tuberculosis Day, TB Alliance and the Medicines Patent Pool (MPP) announced a licensing agreement for the clinical development of sutezolid, an antibiotic … Read more

[MPP Statement] The Medicines Patent Pool Publishes 2017 Prioritization Report Targeting New HIV and Hepatitis C Medicines for In-licensing

Geneva, February 28, 2017 – The Medicines Patent Pool released its 2017 prioritization report today selecting five HIV and two hepatitis C compounds for potential licensing agreements. The annual medicines priority report, traditionally reviewing MPP’s target list for HIV, this year expands to important treatments for the hepatitis C virus … Read more

The Medicines Patent Pool Announces First Licence for Tuberculosis Treatment

In an effort to improve the international response to combatting multidrug-resistant TB, MPP and Johns Hopkins University sign licensing agreement for investigational treatment sutezolid   Geneva, 25 January 2017  — The Medicines Patent Pool today announced that it has signed a licence with Johns Hopkins University to facilitate the clinical … Read more

Sandoz and Beximco Pharmaceuticals Join the Medicines Patent Pool’s Growing Network of Generic Manufacturing Partners

On World AIDS Day, the organisation releases new impact numbers noting progress of generic partners to deliver low-cost, high quality HIV medicines to developing countries Geneva, 1 December 2016  — The Medicines Patent Pool (MPP) today announced the expansion of its network of generic manufacturers to include Sandoz and Beximco … Read more

[MPP Statement] Access to Medicine Index 2016 Published Today with High Marks for Companies that License to the Medicines Patent Pool (MPP)

Biennial ‘Report Card’ also notes that the MPP has been central driver of access-oriented licensing in the pharmaceutical industry (GENEVA, November 14, 2016) – The Access to Medicine (ATM) Index issued its biennial report today giving high marks to companies that have negotiated licences for antiretrovirals and hepatitis C medicines … Read more

The Medicines Patent Pool Announces First World Health Organization Prequalification Submissions for Generic Dolutegravir

Cipla and Mylan are the first companies to apply for WHO’s prequalification of dolutegravir   Geneva, 10 November 2016  — The Medicines Patent Pool (MPP) announced today that two of its generic manufacturing partners are the first companies to apply for prequalification of generic dolutegravir (DTG), a new antiretroviral that … Read more

[MPP Statement] Lancet Commission Report on Essential Medicines for Universal Health Coverage: Identifies Positive Role of Patent Pooling and Voluntary Licensing

Geneva, 08 November 2016 —The Medicines Patent Pool welcomes the report published today by the Lancet Commission on Essential Medicines Policies and its recognition that the MPP model, or a similar approach, could support the international public health commitment to access to essential medicines. The Lancet Commission, a group of … Read more

The Medicines Patent Pool Expands its Expert Advisory Group (EAG) to Include Leaders with Expertise in Hepatitis C and Tuberculosis

Geneva, 10 October 2016 —The MPP announced the expansion of its Expert Advisory Group (EAG), an independent group of advisors providing counsel on licensing agreements, to include eleven new members with hepatitis C and tuberculosis expertise. The newly constituted EAG will now operate in three subgroups focusing on one of … Read more

The Medicines Patent Pool Announces MedsPaL: Its New Medicines Patents & Licences Database

MPP’s signature database upgraded to include patent and licensing data for HIV, hepatitis C and tuberculosis medicines Geneva, 5 October 2016 – The Medicines Patent Pool today announced the launch of MedsPaL, its Medicines Patents & Licences Database, a new resource for information on the intellectual property status of priority … Read more

The Medicines Patent Pool Signs New Round of Generic Manufacturing Licences for HIV and Hepatitis C Treatments

Zydus Cadila joins the MPP as new partner Geneva, 07 July 2016 – The Medicines Patent Pool (MPP) announced new generic manufacturing licences today for four antiretrovirals and hepatitis C direct-acting antiviral daclatasvir. The organisation signed licences with Aurobindo, Desano, Emcure, Hetero Labs, Laurus Labs, Lupin and new partner Zydus … Read more

The Medicines Patent Pool Releases 2015 Annual Report: Five Years of Patent Pooling for Public Health

MPP Reports $195 Million in Savings through Partners’ Supply of Low-Cost Medicines (GENEVA, 26 May 2016) — The Medicines Patent Pool (MPP) released its 2015 Annual Report today reviewing last year’s accomplishments and highlighting its half decade of work in public health-oriented voluntary licensing to improve access to HIV medicines … Read more

ViiV Healthcare, Medicines Patent Pool Extend Licence for Dolutegravir to all Lower Middle-Income Countries

Specifically benefits more than 270,000 people living with HIV in Armenia, Moldova, Morocco and Ukraine   Geneva, 25 April 2016 — The Medicines Patent Pool (MPP) and ViiV Healthcare announced an extension of their current licensing agreement today to increase access to dolutegravir (DTG), a promising new antiretroviral, to cover … Read more

TB Alliance and the Medicines Patent Pool Sign Memorandum of Understanding to Improve Access to TB Medicines in Resource-Limited Nations

  NEW YORK AND GENEVA (April 20, 2016) – TB Alliance and the Medicines Patent Pool (MPP) today announced a Memorandum of Understanding outlining a multi-pronged collaboration to encourage the development of new tuberculosis (TB) regimens and ensure their availability in low-and middle-income countries. The two organisations will work together … Read more

Executive Director Statement on the Appointment of New Chair of the Medicines Patent Pool Governance Board

GENEVA, March 21, 2016 — I am pleased to announce that Sigrun Møgedal has agreed to assume the position of chair of the Medicines Patent Pool (MPP) Governance Board, effective immediately. Sigrun, a long-time member of the Board, takes over the reins from Charles Clift, the founding chair, who served … Read more

The Medicines Patent Pool Signs First Sub-licences for Hepatitis C Medicine Daclatasvir

 Four companies to help speed access to curative direct-acting antiviral in 112 low- and middle-income countries Geneva, 20 January 2016 – The Medicines Patent Pool (MPP) announced its first round of sub-licences for the generic production of Bristol-Myers Squibb’s daclatasvir, a novel direct-acting antiviral that is proven to help cure … Read more

The Medicines Patent Pool and AbbVie Sign Licensing Agreement to Increase Access to Crucial HIV Treatments Throughout Africa

MPP, AbbVie and South African Department of Health work together to establish long-term solutions for antiretroviral therapies (ARVs)   Geneva, 18 December 2015 — The Medicines Patent Pool (MPP) today announced a new licensing agreement with AbbVie, a global biopharmaceutical company, that seeks to address future demands for HIV treatment Lopinavir/Ritonavir (LPV/r) in … Read more

The Medicines Patent Pool welcomes USAID’s selection of two South African organisations to address HIV/AIDS

Geneva, December 11, 2015 –The Medicines Patent Pool welcomes the USAID selection of two leading South African organisations to address the global challenges of HIV treatment announced yesterday in Washington DC and Johannesburg.  One of the new awardees, Wits Reproductive Health Institute, will lead efforts to simplify antiretroviral therapy (ART) as … Read more

The Medicines Patent Pool Signs a Collaborative Agreement with the University of Liverpool to Develop HIV Nanomedicines

Partnership includes an MPP licence for the university’s Solid Drug Nanoparticle (SDN) Technology; Aims to support treatment scale-up through cost cuts of priority antiretrovirals (ARVs) Geneva, 1 December 2015 — The Medicines Patent Pool (MPP) today announced a collaboration with the University of Liverpool and a licence for the university’s Solid Drug … Read more

MPP Statement on WHO Policy Brief: Consolidated Guidelines on the Use of Antiretrovirals (ARV) in the Treatment of HIV

On the eve of World AIDS Day, the Medicines Patent Pool welcomes the publication of the World Health Organization’s policy brief: “Consolidated guidelines on the use of antiretroviral drugs in treating and preventing HIV infection.” The WHO issued the new guideline directions on November 27 for discussion at the International … Read more

The Medicines Patent Pool Signs Licence with Bristol-Myers Squibb to Increase Access to Hepatitis C Medicine Daclatasvir

The royalty-free agreement allows manufacturers to develop daclatasvir for 112 low- and middle-income countries Geneva, 23 November 2015 — The Medicines Patent Pool (MPP) today announced its first licence for a hepatitis C medicine, signing an agreement with Bristol-Myers Squibb for daclatasvir, a novel direct-acting antiviral that is proven to … Read more

The Medicines Patent Pool Statement on US Food and Drug Administration Approval of Tenofovir Alafenamide (TAF) Single Tablet Regimen

Geneva, 6 November 2015 – The Medicines Patent Pool welcomes the US Food and Drug Administration (FDA)’s approval of Gilead Sciences’ tenofovir alafenamide (TAF) single tablet regimen. Genvoya®, a  four-in-one combination of TAF, elvitegravir (EVG), emtricitabine (FTC), and cobicistat (COBI) is the first TAF product to receive positive FDA review … Read more

The Medicines Patent Pool Expands Mandate to Hepatitis C and Tuberculosis Treatment

MPP’s voluntary licensing work could benefit millions of patients in low- and middle-income countries Geneva, 6 November 2015 – The Medicines Patent Pool (MPP), the world’s only voluntary licensing mechanism in public health, announced an expansion of its mandate today to hepatitis C and tuberculosis medicines. The UNITAID Executive Board, … Read more

The Medicines Patent Pool Announces Expansion of its Governance Board

Four new experts in access to medicines, intellectual property and industry will help guide foundation in coming years  Geneva, 27 October 2015 — The Medicines Patent Pool (MPP) announced an expansion of its governance board today with the appointment of four new members: Dr. Claudia Chamas, senior researcher at Brazil’s … Read more

The Medicines Patent Pool Statement on World Health Organization New HIV “Treat-All” Recommendation

GENEVA, September 30, 2015 – The Medicines Patent Pool welcomes the WHO’s announcement today of its new “treat-all” recommendation for people living with HIV. The new guidance, based on recent studies that confirm the benefits of starting antiretroviral therapy as soon after diagnosis as possible, removes all limitations on ART … Read more

The Medicines Patent Pool welcomes initiative from UNICEF and the Global Fund in Ukraine

The Medicines Patent Pool (MPP) welcomes the positive outcome of the initiative from UNICEF and the Global Fund to ensure people living with HIV in conflict-affected areas in Ukraine receive the antiretroviral medicines they need. In the announcement released yesterday, UNICEF indicated that the first consignment of antiretroviral medicines has arrived … Read more

The Medicine Patent Pool Statement on the Addis Ababa Action Agenda: Third International Conference on Financing for Development

The Medicines Patent Pool (MPP) welcomes the agreement brokered by heads of state and government at the UN Third International Conference on Financing for Development held in Addis Ababa this past week. The Addis Ababa Action Agenda establishes a “global framework for financing development post-2015,” as a foundation of global … Read more

The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals

Lupin, Strides, HEC Group, Huahai Bring Total Number of MPP Sub-licensees to Fourteen Companies   Geneva, 01 July 2015 – The Medicines Patent Pool (MPP) announced the rapid expansion of its network of generic manufacturers to 14 companies now working on more than 50 projects to develop MPP-licensed antiretrovirals (ARVs). … Read more

The Medicines Patent Pool and Gilead Sciences Expand Licence to Allow Generic Manufacture of Medicines in South Africa

Geneva, 11 June 2015 – The Medicines Patent Pool (MPP) announced an expansion of its current licensing agreement with Gilead Sciences for generic manufacture of tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF) and other Gilead medicines. The amendment enhances MPP’s current licence by allowing South African manufacturers to join Indian … Read more

The Medicines Patent Pool Announces Two New Chinese Generic Partners

Huahai and HEC Pharm join other MPP licensees in helping speed availability of generic versions of Gilead Sciences’ medicines to low- and middle-income countries Geneva, 9 June 2015 — The Medicines Patent Pool (MPP) announced today that Zhejiang Huahai Pharmaceutical, a large manufacturer of active pharmaceutical ingredients (API) and drug products … Read more

The Medicines Patent Pool Releases 2014 Annual Report: Highlights Progress in Increasing Access to HIV Medicines

MPP signed 20 licensing agreements last year and is now working with 10 generic manufacturers on more than 50 medicine development projects (GENEVA, 20 May 2015) — The Medicines Patent Pool (MPP) released its 2014 Annual Report today highlighting significant steps to increase access to WHO-recommended HIV medicines in low- … Read more

The Medicines Patent Pool on Janssen’s Extension of its Access Policy for Paediatric Medicine Darunavir (Statement)

The MPP welcomes Janssen’s announcement today extending its access policy for paediatric formulations of darunavir in support of the Paediatric HIV Treatment Initiative (PHTI). The company’s new policy to waive enforcement of any patent rights for paediatric formulations of darunavir in additional countries, along with its commitment to providing technical … Read more

The Medicines Patent Pool on Potential Extension of its Mandate to Hepatitis C and Tuberculosis (Statement)

The MPP acknowledges the recent response and input from various civil society organisations and treatment groups on the Foundation’s ongoing assessments to determine the feasibility of extending its mandate to include medicines for hepatitis C (HCV) and tuberculosis (TB). At the request of the UNITAID Executive Board, MPP has been exploring whether, … Read more

The Medicines Patent Pool Welcomes World Health Organization’s First Guide for Hepatitis B Care, Prevention and Treatment (STATEMENT)

The Medicines Patent Pool (MPP) welcomes the WHO’s first-ever Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection issued today in advance of the Asian Pacific Association for the Study of the Liver (APASL) conference in Istanbul.  The WHO confirms that chronic hepatitis B is a major public health problem. … Read more

The Medicines Patent Pool Signs Licensing Agreement with MSD for Paediatric Formulations of Raltegravir

Company joins five other MPP patent holders in efforts to improve HIV paediatric care (GENEVA, 24 February 2015) — The Medicines Patent Pool (MPP) announced a licence today with MSD, known as Merck in the United States and Canada, for paediatric formulations of raltegravir, a key medicine approved for children … Read more

The Medicines Patent Pool (MPP) Signs Licensing Agreement with AbbVie for HIV Paediatric Formulations of Lopinavir and Ritonavir

Licence will support the work of the recently launched Paediatric HIV Treatment Initiative (PHTI) to Develop Better Adapted Medicines for Children Living with the Virus  GENEVA, December 1, 2014 – On World AIDS Day, the Medicines Patent Pool (MPP) and AbbVie announced a licensing agreement for lopinavir (LPV) and ritonavir … Read more

Extension of the 2013 MPP-ViiV Healthcare Licence for Abacavir (Statement)

The Medicines Patent Pool is pleased to announce that the MPP-ViiV Healthcare licence agreement on abacavir (ABC) signed in 2013 has been expanded to include three additional middle-income countries: Ukraine, Venezuela and Peru.  In February 2013,  MPP and ViiV Healthcare launched a broad collaboration on HIV paediatrics that included a … Read more

Access to Medicine Index Applauds the Medicines Patent Pool for High Standard Licences

(GENEVA, November 17, 2014) —The Medicines Patent Pool welcomes the release of this year’s Access to Medicine index and its focus on pro-access voluntary licensing as key to improving public health outcomes in developing countries. After assessing a wide range of voluntary licences for its patent and licensing category, ATM … Read more

The Medicines Patent Pool Adds New Sub-Licensing Agreements to Improve Access to Novel ARVs in Developing Countries

MPP signs sub-licences with six generic manufacturers for the development of Phase III drug Tenofovir Alafenamide Geneva – 25 September 2014.  Two months after signing a licence with Gilead Sciences, Inc. for the company’s novel investigational medicine tenofovir alafenamide (TAF), MPP announced six new sub-licences with Aurobindo, Cipla, Desano, Emcure, … Read more

Paediatric HIV Treatment Initiative (PHTI) To Spur Innovation And Access To Improve The Lives Of Children Living With HIV

  UNITAID, DNDi, and the Medicines Patent Pool Gather Global Experts, Health Ministries, and Industry Leaders in Support of the Initiative to Expedite Development and Delivery of New Antiretroviral Formulations – Geneva – 19 May 2014.  On the eve of the 67th World Health Assembly, Ministers of Health from over … Read more

UNITAID and the Medicines Patent Pool release the new “Patents and Licences on Antiretrovirals” publication

The report provides an overview of the patent and licencing status of a select number of antiretroviral medicines in developing countries. Focusing mainly on ARVs recommended by the World Health Organization the document analyses also data regarding new ARVs that have either recently obtained regulatory approval or are in Phase … Read more

Experts at WHO Say Patent Pools Can Stimulate Research, Medicines Access

Patent pools are one of the proposals likely to be effective in stimulating new research and development of medicines needed in developing countries, a WHO expert report has just concluded. The report, which also recommends the international community negotiate a binding agreement on research and development on diseases disproportionately affecting developing countries, will be discussed at a WHO briefing 27 April. Read more

Johnson & Johnson Says “No” to Joining the Medicines Patent Pool

BRUSSELS, 19 DECEMBER 2011: Today, Johnson & Johnson informed the Medicines Patent Pool of its decision not to license its HIV medicines patents for use in developing countries through the Pool. The Pool, founded and financed by UNITAID, seeks to increase access to HIV medicines by negotiating with pharmaceutical companies … Read more

UNITAID Continues Funding for Pool; Paediatric AIDS

At a meeting in Paris on 12-13 December, UNITAID decided to continue funding the Medicines Patent Pool for the next four years. UNITAID support was critical to the Pool’s creation and will continue to be critical going forward. The Pool is pleased at this endorsement of its success in its … Read more

Pool Governance Board Chairman’s Summary Available

On 8 December, 2011, the Pool’s Governance Board met in London, England. Key decisions included: a new consultative mechanism for the Pool, plans for an expansion of the Pool’s Expert Advisory Group, and an adoption of the Pool’s by-laws. Read more

Event: Innovation in Antiretrovirals to Meet Developing Country Needs

On 10-11 July 2011, the Medicines Patent Pool, UNITAID, WHO and the Chatham House brought together invited experts and representatives working on the treatment of HIV to identify challenges and opportunities for innovation in antiretroviral treatment specifically aimed at the needs of developing countries. Read more

Missing Drug Formulations for HIV Treatment

GENEVA: The Medicines Patent Pool, UNITAID, and the World Health Organization HIV/AIDS Department made a joint submission to the WHO Expert Committee on Essential Medicines on 18 February. The submission was endorsed by nine core partners of the WHO “Treatment 2.0” Initiative for meeting current and future needs of people living with HIV, including UNAIDS, Médecins Sans Frontières (MSF), the US President’s Emergency Plan for AIDS Relief (PEPFAR), and the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Click here to read the submission. Read more